Mesothelioma: trials for referral
111 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
111 trials shown
Phase 1/223 sites
RecruitingSwitzerland, Denmark, Spain, Finland, France, United Kingdom
NCT07563738
A 2-part Phase 1/2 Open-label Trial on ODM-212
Orion Corporation, Orion Pharma
Pre-treatment window Registry sentence: “Sotorasib cohort, treatment naïve: Participants with histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC and a KRAS G12C-mutation, confirmed using a validated test, who are eligible for a treatment with sotorasib and have not received a KRAS G12C inhibitor as prior treatment.”
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT04847063
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06885697
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 1/213 sites
RecruitingPuerto Rico, United States
NCT03556228
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 1/267 sites
RecruitingChina, Japan, South Korea, United States
NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 1/23 sites
RecruitingChina
NCT07885319
Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
Ruijin Hospital
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 18 sites
RecruitingUnited States
NCT06251310
SW-682 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 1/216 sites
RecruitingUnited States
NCT06710756
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 241 sites
RecruitingUnited States
NCT05001880
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Histologically or cytologically confirmed malignant peritoneal mesothelioma for which there has been no prior treatment.”
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingChina
NCT07893340
First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal Mesothelioma
Fudan University
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govEarly Phase 10 sites
Not yet recruiting
NCT07892300
Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer
Oliver Jonas
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 13 sites
RecruitingUnited States
NCT07705334
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
SHY Therapeutics
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT05960773
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Cancer Institute (NCI)
Registry updated 16 Oct 2026
Registry record: ClinicalTrials.govPhase 17 sites
RecruitingUnited States
NCT06623396
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 1/26 sites
RecruitingUnited States
NCT06239194
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 1/22 sites
RecruitingUnited States
NCT05932199
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Baylor College of Medicine
Registry updated 2 Oct 2026
Registry record: ClinicalTrials.govPhase 1/26 sites
RecruitingUnited Kingdom
NCT05944237
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
Registry updated 1 Oct 2026
Registry record: ClinicalTrials.govPhase 13 sites
RecruitingAustralia
NCT07713732
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
Treeline Biosciences, Inc.
Registry updated 1 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingNetherlands
NCT05304208
dENdritic Cell Therapy Combined With SURgEry in Mesothelioma
Erasmus Medical Center
Registry updated 29 Sept 2026
Registry record: ClinicalTrials.govPhase 123 sites
RecruitingUnited States
NCT07277413
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Registry updated 28 Sept 2026
Registry record: ClinicalTrials.govPhase 213 sites
RecruitingUnited States
NCT06057935
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
Registry updated 24 Sept 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07824986
A Phase 3 Trial in Advanced Epithelioid Mesothelioma
Vivace Therapeutics, Inc
Registry updated 17 Sept 2026
Registry record: ClinicalTrials.govPhase 17 sites
RecruitingUnited States
NCT07532902
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Pre-treatment window Registry sentence: “For Diffuse Pleural Mesothelioma (DPM) and Gastroesophageal Carcinoma (GEC )cohorts: no prior systemic treatment for metastatic disease”
Registry updated 16 Sept 2026
Registry record: ClinicalTrials.govPhase 1/210 sites
RecruitingChina, United States
NCT06566079
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
InSilico Medicine Hong Kong Limited
Registry updated 16 Sept 2026
Registry record: ClinicalTrials.govPhase 1/22 sites
RecruitingUnited States
NCT04969315
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Portage Biotech
Registry updated 15 Sept 2026
Registry record: ClinicalTrials.govPhase 270 sites
RecruitingAustralia, Brazil, Canada, China, Germany, United Kingdom
NCT06535607
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
AstraZeneca
Pre-treatment window Registry sentence: “For substudy 5: Participants with any prior systemic therapy, non-palliative radiotherapy, radical pleuropneumonectomy for pleural mesothelioma.”
Registry updated 11 Sept 2026
Registry record: ClinicalTrials.govPhase 1/226 sites
RecruitingSpain, France, United States
NCT05732831
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Registry updated 8 Sept 2026
Registry record: ClinicalTrials.govPhase 124 sites
RecruitingUnited States
NCT05245500
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Bristol-Myers Squibb
Registry updated 2 Sept 2026
Registry record: ClinicalTrials.govPhase 1/276 sites
RecruitingSpain, France, United Kingdom, Italy, South Korea, Poland
NCT04104776
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
Registry updated 19 Aug 2026
Registry record: ClinicalTrials.govPhase 237 sites
RecruitingFrance
NCT07234058
Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
Intergroupe Francophone de Cancerologie Thoracique
Registry updated 11 Aug 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States54 open trials
- China15 open trials
- Italy13 open trials
- France11 open trials
- United Kingdom9 open trials
- Netherlands5 open trials
- Spain3 open trials
- Japan3 open trials
- South Korea3 open trials
- Australia3 open trials
- Belgium3 open trials
- Switzerland2 open trials
- Denmark2 open trials
- Germany2 open trials
- Finland1 open trials
- Puerto Rico1 open trials
- Canada1 open trials
- Vietnam1 open trials
- Taiwan1 open trials
- Brazil1 open trials
- Poland1 open trials
- Greece1 open trials
- Norway1 open trials
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Naples, Italy
1 trials · 11 publications · ROR
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, United States
5 trials · 9 publications · ROR
The Ohio State University Wexner Medical Center
Columbus, United States
1 trials · 11 publications · ROR
The University of Texas MD Anderson Cancer Center
Houston, United States
9 trials · 40 publications · ROR
The University of Texas Southwestern Medical Center
Dallas, United States
5 trials · 11 publications · ROR
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
1 trials · 33 publications · ROR
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
Turin, Italy
0 trials · 9 publications · ROR
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
0 trials · 25 publications · ROR
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
0 trials · 24 publications · ROR
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
0 trials · 18 publications · ROR
Hangzhou Institute of Medicine, Chinese Academy of Sciences
Hangzhou, China
0 trials · 11 publications · ROR
Istituto Nazionale per l'Assicurazione Contro gli Infortuni sul Lavoro
Rome, Italy
0 trials · 15 publications · ROR
Manchester University NHS Foundation Trust
Manchester, United Kingdom
0 trials · 13 publications · ROR
Northumbria Healthcare NHS Foundation Trust
North Shields, United Kingdom
0 trials · 11 publications · ROR
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom
0 trials · 11 publications · ROR
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
0 trials · 8 publications · ROR
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
Vercelli, Italy
0 trials · 18 publications · ROR
University of Occupational and Environmental Health Japan
Kitakyushu, Japan
0 trials · 9 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Stopped early
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT06756035 · Phase 1 · United States
Source: ClinicalTrials.govPhase changed: Phase 1 → Phase 1/2
Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma
NCT05449366 · Phase 1/2 · Netherlands
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT03546426 · Phase 1 · Italy
Source: ClinicalTrials.govPhase changed: Phase 2 → Phase 1/2
Autologous Dendritic Cell Vaccination in Mesothelioma
NCT02649829 · Phase 1/2 · Belgium
Source: ClinicalTrials.govClosed for recruitment
NCT01843374 · Phase 2 · Australia, Belgium, Canada, Germany, Denmark, Spain
Source: ClinicalTrials.govOpened for recruitment
NCT01843374 · Phase 2 · Australia, Belgium, Canada, Germany, Denmark, Spain
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
No phaseEnded 15 Oct 2026
Phase 1Ended 9 Oct 2026
Stopped early19 participants
NCT06756035
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Reason given: The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.
No phaseEnded 5 Aug 2026
Completed125 participants
NCT06581549
Immune Microenvironment and Gene Expression Profiling in Mesothelioma
Phase 1/2Ended 7 May 2026
Completed50 participants
NCT05278975
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
- Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer. · Nature communications, 2026
Phase 1Ended 27 Apr 2026
Completed25 participants
NCT02959463
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
Phase 2Ended 31 Mar 2026
Completed31 participants
NCT05918107
A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM
No phaseEnded 23 Mar 2026
Completed72 participants
NCT05461430
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Phase 2Ended 20 Mar 2026
Phase 3Ended 16 Jan 2026
Completed53 participants
NCT03710876
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
No phaseEnded 1 Jan 2026
Phase 2Ended 20 Dec 2025
Phase 1Ended 12 Dec 2025
Completed58 participants
NCT05800964
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
Phase 1/2Ended 19 Nov 2025
Completed50 participants
NCT05275478
Study to see how safe is TNG908 at different doses in patients with solid tumors that have a gene called MTAP missing
Phase 2Ended 12 Nov 2025
Phase 1Ended 9 Oct 2025
Phase 1/2Ended 29 Sept 2025
Phase 1Ended 23 Sept 2025
Completed147 participants
2023-509542-35-00
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
Phase 1Ended 18 Sept 2025
Completed19 participants
NCT05795595
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
No phaseEnded 27 Aug 2025
Completed204 participants
NCT05308966
Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
Phase 1/2Ended 19 Aug 2025
Completed18 participants
NCT03834272
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Phase 1/2Ended 1 Aug 2025
Completed7 participants
NCT05449366
Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma
Phase 1/2Ended 1 Jul 2025
Completed316 participants
NCT02611024
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
- Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC. · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026
Phase 3Ended 30 Jun 2025
Completed214 participants
NCT04334759
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Phase 1Ended 18 Jun 2025
Completed19 participants
NCT04525859
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
- Phase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection. · The Journal of thoracic and cardiovascular surgery, 2026
Phase 1Ended 30 May 2025
Completed20 participants
NCT04926948
Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
Phase 1Ended 17 Mar 2025
Completed45 participants
NCT05571839
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Phase 1/2Ended 9 Mar 2025
Phase 2Ended 31 Jan 2025
Phase 2Ended 30 Jan 2025
Completed92 participants
NCT04177953
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Phase 1Ended 22 Nov 2024
Completed48 participants
NCT04672434
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Phase 1Ended 21 Nov 2024
Completed182 participants
NCT04242199
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Phase 3Ended 18 Nov 2024
Completed400 participants
NCT03762018
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
Phase 1Ended 14 Nov 2024
Completed10 participants
NCT04040231
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
No phaseEnded 31 Oct 2024
Completed167 participants
NCT04028479
The Registry of Oncology Outcomes Associated With Testing and Treatment
Phase 1Ended 24 Oct 2024
Phase 2/3Ended 11 Oct 2024
Completed520 participants
NCT02784171
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Phase 2Ended 4 Oct 2024
Phase 4Ended 4 Sept 2024
Completed50 participants
2022-502345-10-00
The effect of oral folinic acid to prevent pemetrexed induced adverse events.
No phaseEnded 1 Sept 2024
Completed40 participants
NCT07869056
Forceps Versus Cryobiopsy in Undiagnosed Exudative Pleural Effusion Using Rigid Thoracoscopy
Phase 2Ended 19 Aug 2024
Phase 1Ended 30 Jul 2024
Phase 1Ended 30 Jun 2024
Completed18 participants
NCT04375267
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
Phase 1Ended 26 Jun 2024
Completed22 participants
NCT05538572
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Phase 2Ended 3 Apr 2024
No phaseEnded 1 Apr 2024
Completed199 participants
NCT04670445
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
Phase 2Ended 1 Apr 2024
Completed40 participants
NCT05660616
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Phase 2Ended 15 Mar 2024
Completed186 participants
NCT03654833
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
Phase 2Ended 20 Feb 2024
Phase 2Ended 1 Feb 2024
Completed47 participants
NCT05005429
Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
Phase 2Ended 26 Jan 2024
Completed34 participants
NCT02611037
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
No phaseEnded 31 Dec 2023
Completed43 participants
NCT04324437
eRAPID: Online Symptom Reporting in Lung Cancer
- Online symptom monitoring for lung cancer patients receiving systemic therapy: a feasibility implementation project. · Journal of thoracic disease, 2026
Phase 4Ended 29 Dec 2023
Phase 1Ended 18 Dec 2023
Completed2 participants
NCT05071014
A Study of Pembrolizumab and Cryoablation in People With Mesothelioma
Not medical advice. fetched 7 Nov 2026